Search results for Guselkumab

Guselkumab Biosimilar – Anti-IL23A mAb – Research Grade, ProteoGenix, PX-TA1327

Description of Guselkumab Biosimilar - Anti-IL23A mAb - Research Grade General information on Anti-IL23A[Homo sapiens] (Guselkumab) Monoclonal Antibody Guselkumab is a human IgG1 lambda monoclonal antibody that targets interleukin-23. IL-23 is an inflammatory cytokine that is reponsible for the activation of the CD4+ T-helper (Th17) cell pathway in the inflammatory cascade that induces psoriatic plaque formation. Guselkumab has been used to treat psoriasis. It has been sold under the trade name Tremfya.

Guselkumab, Abbexa, abx831285

Guselkumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting IL23A, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation 2. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Guselkumab ELISA Kit, ProteoGenix, KPTX380

Description of Guselkumab ELISA Kit Introduction The Guselkumab ELISA Kit is a highly sensitive and specific assay designed for the quantitative detection of Guselkumab in various biological samples. This kit is an essential tool for researchers and clinicians studying the therapeutic target and activity of Guselkumab, a monoclonal antibody used for the treatment of immune-mediated inflammatory diseases. Structure of Guselkumab Guselkumab is a fully human IgG1 monoclonal antibody that specifically targets interleukin-23 (IL-23), a cytokine involved in the pathogenesis of various inflammatory diseases. It is composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The structural integrity of Guselkumab is crucial for its binding to IL-23 and subsequent inhibition of its activity. Activity of Guselkumab Guselkumab exerts its therapeutic effects by selectively binding to the p19 subunit of IL-23, preventing its interaction with the IL-23 receptor and subsequent activation of downstream signaling pathways. This results in a decrease in the production of pro-inflammatory cytokines, such as IL-17 and IL-22, which are responsible for the chronic inflammation observed in diseases such as psoriasis and psoriatic arthritis. Application of Guselkumab ELISA Kit The Guselkumab ELISA Kit is a valuable tool for measuring the levels of Guselkumab in various biological samples, such as serum, plasma, and cell culture supernatants. This assay provides a quantitative measurement of Guselkumab, allowing researchers to accurately determine its concentration in samples and monitor its pharmacokinetics in clinical trials. Furthermore, this kit can also be used to assess the neutralizing activity of Guselkumab, providing valuable information on its inhibitory effects on IL-23. Therapeutic Target of Guselkumab Guselkumab has been approved by the FDA for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. It is also being investigated as a potential therapy for other immune-mediated inflammatory diseases, such as Crohn’s disease and ulcerative colitis. The specific targeting of IL-23 by Guselkumab makes it a promising therapeutic target for these diseases, as it allows for a more targeted and effective treatment approach. Research Use of Guselkumab ELISA Kit In addition to its clinical applications, the Guselkumab ELISA Kit is also widely used in research studies to investigate the role of IL-23 in various inflammatory diseases. By accurately measuring the levels of Guselkumab, researchers can assess its efficacy in inhibiting IL-23 and its downstream effects. This kit has also been used to study the pharmacokinetics of Guselkumab in different patient populations, providing valuable insights into its dosing and administration. Conclusion The Guselkumab ELISA Kit is a highly sensitive and specific assay that plays a crucial role in the research and development of this promising therapeutic agent. Its ability to accurately measure the levels of Guselkumab and assess its activity makes it an essential tool for studying the therapeutic target and potential applications of this monoclonal antibody. With its growing use in both clinical and research settings, the Guselkumab ELISA Kit continues to contribute to our understanding of IL-23 and its role in inflammatory diseases.

Guselkumab ELISA Kit, Abbexa, abx395213

This product is currently in development. The lead time for this product may be several months. Please contact us at [email protected] for an updated lead time before purchasing this product. Guselkumab ELISA Kit is a quantitative ELISA kit for detection of Guselkumab.

Guselkumab Antibody ELISA Kit, Abbexa, abx395214

Guselkumab Antibody ELISA Kit is a quantitative ELISA kit for detection of antibodies against Guselkumab.

Guselkumab Biosimilar - Research Grade, ichor.bio, ICH5064

Detects human IL23. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Guselkumab.

Anti-Guselkumab Non-Neutralizing Antibody (SAA2635), ProteoGenix, PTX27139